Critical Comparison: Omnicell (NASDAQ:OMCL) & NeuroOne Medical Technologies (NASDAQ:NMTC)

NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) and Omnicell (NASDAQ:OMCL – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Profitability

This table compares NeuroOne Medical Technologies and Omnicell’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NeuroOne Medical Technologies -71.50% -128.12% -86.34%
Omnicell 3.59% 5.69% 3.61%

Risk & Volatility

NeuroOne Medical Technologies has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500.

Insider & Institutional Ownership

16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. Comparatively, 97.7% of Omnicell shares are owned by institutional investors. 11.8% of NeuroOne Medical Technologies shares are owned by company insiders. Comparatively, 2.9% of Omnicell shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for NeuroOne Medical Technologies and Omnicell, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeuroOne Medical Technologies 1 1 3 0 2.40
Omnicell 0 2 7 1 2.90

NeuroOne Medical Technologies presently has a consensus target price of $7.33, suggesting a potential upside of 1,024.57%. Omnicell has a consensus target price of $57.86, suggesting a potential upside of 77.97%. Given NeuroOne Medical Technologies’ higher probable upside, equities research analysts clearly believe NeuroOne Medical Technologies is more favorable than Omnicell.

Earnings & Valuation

This table compares NeuroOne Medical Technologies and Omnicell”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NeuroOne Medical Technologies $12.10 million 0.49 -$3.61 million ($0.95) -0.69
Omnicell $1.24 billion 1.20 $2.05 million $0.96 33.86

Omnicell has higher revenue and earnings than NeuroOne Medical Technologies. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Summary

Omnicell beats NeuroOne Medical Technologies on 12 of the 15 factors compared between the two stocks.

About NeuroOne Medical Technologies

(Get Free Report)

NeuroOne Medical Technologies develops medical devices that use thin-film electrode technology for diagnosing and treating neurological disorders. Its products are designed for use by clinicians in procedures involving the brain and nervous system. The company’s portfolio includes Evo cortical and stereoelectroencephalography (sEEG) electrodes, which are used to record brain activity, and the OneRF system, designed to deliver radiofrequency ablation and stimulation. These technologies are intended to support applications including epilepsy diagnosis and treatment.

About Omnicell

(Get Free Report)

Omnicell, Inc. develops medication-management solutions for healthcare providers. Its products and services are designed to help manage medication storage, dispensing, inventory and workflows across healthcare settings. The company offers automated dispensing cabinets for patient-care areas, automation systems for central pharmacies, and software and analytics that support medication management. Its solutions serve hospitals, health systems, pharmacies and other care providers, including long-term and post-acute care organizations.

Receive News & Ratings for NeuroOne Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroOne Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.